We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Brilinta

News List

PhaseBio nets $34M to advance Brilinta reversal agent, PAH drug fiercebiotech
September 06, 2018
PhaseBio is using its ELP platform to extend the half-life of proteins, peptides and other large molecules to create injectable drugs that can be administered less frequently.
With two new uses kaput, AstraZeneca touts more long-term Brilinta data at ESC fiercepharma
August 25, 2017
In a new analysis of older trial data, Brilinta showed it could cut the risk of cardiovascular death by 29% compared with placebo.
Extended use of AstraZeneca's Brilinta reduces cardiovascular death risk pharmafile
August 25, 2017
New data for AstraZeneca’s blood thinner Brilinta (ticagrelor) has shown that extended use of the drug can cut the risk of heart attacks by almost a third in patients with a history of such atherothrombotic events.
Extended treatment with Brilinta reduces risk of cardiovascular death by 29% in patients with histor worldpharmanews
August 25, 2017
AstraZeneca today announced results from a new sub-analysis of data from the Phase III PEGASUS-TIMI 54 trial demonstrating a 29% risk reduction in ...

Previous page 1 2 Next page